Navigation Links
Magellan Biosciences Sells its Life Sciences Tools Business to Dionex
Date:9/22/2009

CHELMSFORD, Mass., Sept. 22 /PRNewswire/ -- Magellan Biosciences, Inc. (Magellan), an emerging leader in clinical diagnostics, has sold its ESA Life Sciences Tools (LST) business to Sunnyvale, California-based Dionex, Inc. (Nasdaq: DNEX). The sale includes all of ESA's HPLC-related products, HPLC clinical assays, the ESA Laboratories services and assets, as well as ESA's headquarters in Chelmsford, Massachusetts. Financial terms of the transaction were not disclosed.

"This sale enables Magellan to concentrate on our clinical-diagnostic customers. We can now apply all of our resources to developing and supporting innovation in diagnostic products that give clinicians the answers they need to make more-informed treatment decisions for superior, outcomes-based care," said Magellan President and Chief Executive Officer, Robert J. Rosenthal, Ph.D. "Stay tuned. Over the next several months we will be highlighting the new diagnostics-focused Magellan. In the meantime, customers can continue to count on the Magellan brands and people they've come to know: LeadCare((R) )for( )blood-lead-testing systems, Dynex((R)) for automated ELISA processing systems, and TREK for microbiology."

LeadCare - Because traditional prescription-based and send-out practices have missed those children most at-risk for lead poisoning, policy-makers at the federal, state, and local level are taking action to encourage the use of the LeadCare II system to ensure that children receive mandated testing. For example, New York State Medicaid just began reimbursing doctors and health clinics for LeadCare II tests. As a CLIA-waived test, the LeadCare II system removes all the complications formerly associated with blood-lead testing - waiting days for lab results, spending precious staff time and resources trying to contact patients for critical follow-up care, or tracking down results for record-keeping, reporting, or compliance purposes. Visit www.WaivedLeadCare.com to learn more. For important lead-poisoning prevention resources, links to consumer product recall information, and tips for keeping children safe, visit www.LeadPoisonInfo.com.

Dynex - The DS2(R) two-plate and DSX(R) four-plate ELISA processing systems are designed for efficiency and reliability with the 'expert' inside. They perform the most-sophisticated analyses, but are easy to use for operators with varying levels of education and experience. The DSX and DS2 are open systems with full walk-away automation and precise liquid-handling capabilities. They execute the entire complement of analytical steps required for virtually any ELISA immunoassay: adding samples and reagents, washing, incubation, and detection, delivering all you need to ensure the rigorous, repeatable analyses required in critical applications - from immunology to infectious disease, hormone, allergy, blood-chemistry, and drugs-of-abuse testing. To see a video of the DS2 at work, visit www.dynextechnologies.com.

TREK - The award-winning VersaTREK(R) automated microbial-detection system performs four tests on one automated platform: culture for blood, sterile body fluids, and mycobacteria detection, as well as Mycobacterium tuberculosis (TB) susceptibility testing. TREK's signature Sensititre(R) product line for susceptibility and identification testing enables labs to test - on a single cost-effective, LIS-compatible system - more FDA-cleared antimicrobial drugs than on any other automated platform against the widest range of non-fastidious and fastidious bacteria and yeasts. This saves microbiology labs from having to use multiple off-line test procedures to obtain accurate susceptibility data. TREK's platform is the system-of-choice for global surveillance initiatives, including NARMS (National Antimicrobial Resistance Monitoring System). For more information on TREK products, visit www.trekds.com.

About Magellan (www.magellanbio.com)

An emerging leader in clinical-diagnostic markets for near-patient testing, hospital-based labs, and microbiology, Magellan serves customers worldwide with rapid point-of-care analyzers and consumables; blood culture, antimicrobic-susceptibility tests, systems, and reagents; as well as automated ELISA processing systems, microplate instrumentation, and associated consumables. We design all our products to deliver better, faster, more-reliable diagnostic results to help doctors make more-informed treatment decisions and improve health outcomes. Magellan brands include LeadCare, Dynex, and TREK.


'/>"/>
SOURCE Magellan Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Intrinsic Therapeutics Barricaid and Magellan Spine Technologies DART to Drive European Annulus Repair Market
2. Magellan Biosciences Companies to Feature Diagnostic Products Designed to Improve Health Outcomes at the Clinical Lab Expo
3. Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System
4. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
5. Cell Biosciences Launches Unique Protein Phosphorylation Assay Service
6. Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences(R) to Provide World-Class Fluid Management and Liquid/Powder System Solutions
7. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
8. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
9. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
10. BD Biosciences Launches New Cell Analyzer for Complex Multicolor Experiments in Disease and Drug Development Research
11. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... LLC, announced the first national #QuackGivesBack campaign which supported local breast cancer ... our first franchise-wide Quack Gives Back initiative, and we’re very pleased ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading ... has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE ... Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage Lung ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... modes of access for customers and employees that are both engaging and easy ... with Service Smart Technology, the software company revealed today its plans to roll ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Vida ... raised an $18M Series B led by Canvas Ventures . Other investors include ... to scale its mobile platform to serve more consumers who are managing chronic ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec 9, 2016 Research and ... Market 2016-2020" report to their offering. ... The global travel vaccines market to ... The report covers the present scenario and the growth prospects ... market size, the report considers the revenue generated from the sales ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016 IRIDEX Corporation ... to offer newly issued shares of common stock, $0.01 par ... to an underwritten public offering.  The final terms of the ... time of pricing, and there can be no assurance as ... IRIDEX expects to use the net proceeds it will ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016  The global ... of 8.8% during the forecast period of 2016 to ... billion by 2021 from USD 18.21 billion in 2016. ... surgeries, rising incidences of sports related injuries and spinal ... and rising need of effective blood loss management. ...
Breaking Medicine Technology: